A Study of GH21 Combined With Previous Target Therapy or Immunotherapy in Patients With Advanced Solid Tumors

NCT06322095 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

72

Enrollment

OTHER

Sponsor class

Conditions

Patients With Advanced Solid Tumor
Advanced Solid Tumor With Oncogenic Driver Mutations

Interventions

DRUG: PD-1
DRUG: MET inhibitor
DRUG: ALK inhibitor
DRUG: BRAF Inhibito
DRUG: EGFR Monoclonal antibody
DRUG: GH21
DRUG: MEK Inhibitor

Sponsor

Suzhou Genhouse Bio Co., Ltd.